Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Gonzalez
A
A
Everall
I P
IP
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001812:Blood-Brain Barrier; D002490:Central Nervous System / Q000187:drug effects; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D003704:Dementia; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D001523:Mental Disorders / Q000150:complications* / Q000188:drug therapy*; D019829:Nevirapine / Q000009:adverse effects / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D000099227:Abacavir
D019380:Anti-HIV Agents; D014150:Antipsychotic Agents; D003577:Cytochrome P-450 Enzyme System; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019829:Nevirapine; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir